The development cost and timeline for a new drug is increasing due to high attrition rates caused by inadequate physicochemical and biopharmaceutical attributes, unacceptable safety, and sub-marginal efficacy. This development attrition rate can be reduced by strengthening efficacy and toxicity screens and establishing a developability screen to enable selection of developable compounds to move to the clinic. It is critical to select right formulation principles for efficacy and toxicity screens, and equally important to run developability screens by:
Key Learning Objectives:
Who Should Attend:
For questions please contact Martha Devia: email@example.com
As part of our commitment to providing education to healthcare and industry sciences professionals during the COVID-19 pandemic, attendance at this webinar is free of charge. However, if you’d like to make a donation to help first responders through the New Jersey Pandemic Relief Fund, MJH Life Sciences™ will match all contributions. To make a donation, please click “donate” below and complete the requested information.